Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 14/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450320 | 0.81 | DGAT1 (0.42) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL3377209 | 0.81 | DGAT1 (0.42) | — | |
| SCHEMBL3448683 | 0.80 | GAA (0.41) | ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL3448094 | 0.79 | KDM4E (0.50) | TBXAS1ALDH1A1KDM4EAHRNPSR1 | |
| SCHEMBL3348530 | 0.79 | DGAT1 (0.40) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL3373097 | 0.78 | TBXAS1 (0.47) | TBXAS1ALDH1A1KDM4EAHRNPSR1 | |
| SCHEMBL789862 | 0.78 | ALPL (0.46) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL29604061 | 0.78 | ALPL (0.46) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL3448376 | 0.75 | DGAT1 (0.46) | — | |
| SCHEMBL1561030 | 0.72 | ALDH1A1 (0.61) | TBXAS1ALDH1A1KDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | TBXAS1 736/4885ALDH1A1 530/4885KDM4E 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.